News
ABVC
0.7489
+4.01%
0.0289
ABVC BioPharma Corrects Licensing Deal Financials
TipRanks · 3d ago
ABVC BIOPHARMA INC -CEO UTTAM PATIL WILL ASSUME DUTIES OF INTERIM CFO UNTIL PARTIES SETTLE DISAGREEMENT AND LEEDS RESUMES HIS POSITION AS CFO
Reuters · 3d ago
Weekly Report: what happened at ABVC last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at ABVC last week (0708-0712)?
Weekly Report · 07/15 10:52
Weekly Report: what happened at ABVC last week (0701-0705)?
Weekly Report · 07/08 10:53
Abvc Biopharma Inc: Notice of Effectiveness
Press release · 07/02 12:19
Weekly Report: what happened at ABVC last week (0624-0628)?
Weekly Report · 07/01 10:54
Weekly Report: what happened at ABVC last week (0617-0621)?
Weekly Report · 06/24 11:00
ABVC Biopharma files to sell 1M shares of common stock for holders
ABVC Biopharma files to sell 1M shares of common stock for holders Jun. 21, 2024. ABVC BioPharma, Inc. Filed a prospectus related to the offer and resale of up to 1,000,000 shares of stock. This prospectus is not an offer to sell.
Seeking Alpha · 06/21 21:26
Weekly Report: what happened at ABVC last week (0610-0614)?
Weekly Report · 06/17 10:53
Weekly Report: what happened at ABVC last week (0603-0607)?
Weekly Report · 06/10 10:54
Weekly Report: what happened at ABVC last week (0527-0531)?
Weekly Report · 06/03 10:57
Weekly Report: what happened at ABVC last week (0520-0524)?
Weekly Report · 05/27 11:01
ABVC Biopharma & Biolite Entered Into Definitive Agreement With Oncox Biopharma To Collaborate On Combination Therapy; ABVC & Unit Are Eligible To Receive Aggregate License Fee Of $12.5M In Form Of Cash Or Shares Of Oncox Securities; Under Terms Of Deal, ABVC Grants Oncox Exclusive Rights For One Of ABVC's 4 Products In Its Oncology Pipeline
Benzinga · 05/24 12:17
ABVC BIOPHARMA- UNDER TERMS OF DEAL, ABVC GRANTS ONCOX EXCLUSIVE RIGHTS FOR ONE OF ABVC’S FOUR PRODUCTS IN ITS ONCOLOGY PIPELINE
Reuters · 05/24 12:02
ABVC BIOPHARMA- CO & BIOLITE ENTERED INTO DEFINITIVE AGREEMENT WITH ONCOX BIOPHARMA TO COLLABORATE ON COMBINATION THERAPY
Reuters · 05/24 12:02
ABVC BIOPHARMA- ABVC & UNIT ARE ELIGIBLE TO RECEIVE AGGREGATE LICENSE FEE OF $12.5 MLN IN FORM OF CASH OR SHARES OF ONCOX SECURITIES
Reuters · 05/24 12:02
Weekly Report: what happened at ABVC last week (0513-0517)?
Weekly Report · 05/20 10:55
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024
ABVC BioPharma just reported results for the first quarter of 2024. The company reported earnings per share of -40 cents and revenue of $1,205. ABVC Biopharma is a biopharmaceutical company with a focus on cancer drugs and vaccines.
Investorplace · 05/18 02:52
ABVC BioPharma, Inc. Quarterly Report on Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/18 02:41
More
Webull provides a variety of real-time ABVC stock news. You can receive the latest news about Abvc Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABVC
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.